Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
SOPHiA GENETICS (Nasdaq: SOPH) announced a new multi-year global collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The agreement will advance two CDx programs using SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities.
According to SOPHiA GENETICS, its Solid Tumor application will be developed into a decentralized CDx, and its Hematological Oncology application will be developed and validated to support a CDx program for patients with blood cancer. The CDx solutions are intended to combine accurate biomarker detection with rapid, global deployment via the cloud-based SOPHiA DDM platform and the SOPHiA DDM MaxCare Program, allowing local laboratories worldwide to run the same validated, AI-powered analysis. SOPHiA GENETICS highlights that its technology-agnostic network connects more than 1,000 institutions across over 75 countries, aiming to expand access to innovative oncology treatments and support informed clinical decision-making in multiple healthcare systems.
AstraZeneca (AZN) and Daiichi Sankyo received European Commission approval for Datroway (datopotamab deruxtecan) as first-line monotherapy for adults with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Approval is based on the phase 3 TROPION-Breast02 trial, where Datroway improved median overall survival by 5.0 months versus chemotherapy (23.7 vs 18.7 months; HR=0.79; p=0.0291) and reduced risk of disease progression or death by 43% (HR=0.57; p<0.0001). Median progression-free survival was 10.8 vs 5.6 months, and objective response rate was 62.5% vs 29.3% with chemotherapy. Datroway is now approved in the EU for two breast cancer indications and is the only TROP2-directed ADC in the EU with demonstrated overall survival benefit in first-line metastatic TNBC, according to Daiichi Sankyo.
AstraZeneca (NYSE: AZN) reported positive high-level results from the global Phase III CLARITY-Gastric01 trial, in which sonesitatug vedotin (Sone‑Ve), an anti‑CLDN18.2 antibody-drug conjugate, showed a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus investigator’s choice of therapy in 3rd and later-line CLDN18.2‑positive advanced gastric, gastroesophageal junction (GEJ) cancer and esophageal adenocarcinoma.
The trial enrolled patients whose tumors expressed CLDN18.2 in ≥25% of cells and met its dual primary endpoint of OS in 3rd and later-line treatment, as well as a key secondary endpoint of OS in the overall 2nd and later-line population. Progression‑free survival, the other dual primary endpoint, showed a trend toward improvement in the 2nd and later-line setting but did not reach statistical significance. Sone‑Ve was well tolerated with no new safety signals and is being positioned for a broad CLDN18.2‑positive population, estimated at about 60% of gastric/GEJ cancers, representing roughly 183,500 2nd and later-line patients annually across the US, EU, China and Japan.
AstraZeneca (NASDAQ:AZN) reported H1 2026 Total Revenue of $30.7bn, up 9% reported and 6% at CER, with Product Revenue of $30.6bn. H1 Reported EPS was $3.60 (up 4% reported, 3% CER) and Core EPS was $5.21 (up 12% reported, 11% CER).
Q2 2026 Total Revenue was $15.4bn, up 6% reported and 5% CER, with Gross Margin at 84% and Core Operating Margin at 34%. The interim dividend increased by 3 cents to $1.06 per share. Guidance for 2026 at CER is reconfirmed: Total Revenue to grow mid-to-high single digits and Core EPS by a low double-digit percentage.
The company highlighted 30 major approvals since Q4 2025, mixed Phase III readouts, and two sizeable licensing deals: a global licence for lung cancer drug Zegfrovy ($600m upfront, up to $900m milestones) and a respiratory PDE3/4 inhibitor TQC3721 ($200m upfront, up to $1.9bn milestones).
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) plus pertuzumab has received a positive CHMP opinion in the EU as first-line treatment for adults with unresectable or metastatic HER2 positive breast cancer. The recommendation, based on the phase 3 DESTINY-Breast09 trial, will now be reviewed by the European Commission.
According to the companies, the combination reduced the risk of disease progression or death by 44% versus taxane + trastuzumab + pertuzumab (THP), with median progression-free survival of 40.7 months versus 26.9 months. Confirmed objective response rate was 85.1% with Enhertu plus pertuzumab versus 78.6% with THP, and median duration of response reached 39.2 months versus 26.4 months. The safety profile was described as consistent with known profiles of each drug; treatment-related grade ≥3 neutropenia occurred in 23.9% of patients and adjudicated interstitial lung disease or pneumonitis in 12.1%, including 0.5% grade 5 events.
Abbisko Therapeutics and AstraZeneca (NYSE:AZN) entered a strategic collaboration to develop an IO-TKI combination for EGFR-mutated, PD-L1 positive NSCLC. A multicenter, open-label Phase I/II trial will test Abbisko’s oral PD-L1 inhibitor lumipodlin (ABSK043) with AstraZeneca’s TAGRISSO (osimertinib). The investigational new drug application for this combination was cleared by China’s NMPA on May 20, 2026, and Abbisko will lead the Phase II study, with both companies sharing trial responsibilities.
AstraZeneca (LSE/STO/NYSE: AZN) and Daiichi Sankyo received European Commission approval for Enhertu as the first tumor-agnostic HER2-directed antibody drug conjugate. The monotherapy is indicated for adults with unresectable or metastatic HER2 positive (IHC 3+) solid tumors after prior treatment and without satisfactory options.
Approval is based on three phase 2 trials (DESTINY-PanTumor02, -Lung01, -CRC02), showing confirmed ORRs of 52.3%, 52.9% and 46.9% and median DORs up to 21.1 months. A $25 million milestone payment is due from AstraZeneca to Daiichi Sankyo.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) received a positive CHMP opinion in the EU as first-line monotherapy for unresectable or metastatic triple negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
TROPION-Breast02 showed 5.0-month median overall survival gain (23.7 vs 18.7 months; HR=0.79) and longer progression-free survival (10.8 vs 5.6 months; HR=0.57) versus chemotherapy, plus higher objective response rate (62.5% vs 29.3%). Datroway is already approved in the US and under review in several other regions.
AstraZeneca (NYSE:AZN) and YMCA of the USA announced a five-year, multimillion-dollar partnership to strengthen community-based cancer education and survivorship support across the US.
The initiative aims to reach 175,000 people in 75 communities in its first two years, focusing on screening, early detection, and evidence-based programs for cancer survivors.
AstraZeneca (NASDAQ:AZN) announced US FDA approval of TRUQAP (capivasertib) plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer, detected by an FDA‑authorized test.
In Phase III CAPItello‑281, the combination reduced risk of radiographic progression or death by 19% (HR 0.81; 95% CI 0.66–0.98; p=0.034) and improved median rPFS to 33.2 vs 25.7 months. Overall survival data are immature but numerically favor the TRUQAP regimen. A companion PTEN diagnostic was approved alongside the indication.
Common Grade ≥3 adverse events with the prostate regimen included rash (12.3%) and hyperglycemia (10.3%), and 20% of patients discontinued TRUQAP due to adverse reactions.